Alaunos Therapeutics (TCRT) Other Operating Expenses (2009 - 2023)

Alaunos Therapeutics (TCRT) has 8 years of Other Operating Expenses data on file, last reported at $3.7 million in Q4 2023.

• Quarterly Other Operating Expenses changed N/A year-over-year to $3.7 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $3.7 million (up 388.12% YoY) and the FY2023 annual result came in at $4.5 million, up 3487.22% from the prior year.
• Other Operating Expenses advanced to $3.7 million in Q4 2023, from $1.0 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $3.7 million in Q4 2023 to a low of -$245000.0 in Q2 2023.
• A 3-year average of $1.0 million and a median of $740000.0 in 2021 frame the typical range for Other Operating Expenses.
• The widest YoY moves for Other Operating Expenses: up 84.21% in 2023, down 84.21% in 2023.
• Tracing TCRT's Other Operating Expenses over 3 years: stood at $740000.0 in 2021, then tumbled by 117.97% to -$133000.0 in 2022, then soared by 2911.28% to $3.7 million in 2023.
• The last three Other Operating Expenses figures came in at $3.7 million (Q4 2023), $1.0 million (Q3 2023), and -$245000.0 (Q2 2023), per Business Quant data.